Log in

NASDAQ:DMAC - DiaMedica Therapeutics Stock Price, Forecast & News

$2.81
-0.02 (-0.71 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
$2.72
Now: $2.81
$3.07
50-Day Range
$2.25
MA: $4.14
$5.64
52-Week Range
$1.70
Now: $2.81
$5.93
Volume59,180 shs
Average Volume51,532 shs
Market Capitalization$33.61 million
P/E RatioN/A
Dividend YieldN/A
Beta2.57
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Read More

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DMAC
CUSIPN/A
CIKN/A
Phone763-312-6755

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$500,000.00
Book Value$1.43 per share

Profitability

Net Income$-5,730,000.00

Miscellaneous

Employees9
Market Cap$33.61 million
Next Earnings Date5/11/2020 (Estimated)
OptionableNot Optionable

Receive DMAC News and Ratings via Email

Sign-up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter.


DiaMedica Therapeutics (NASDAQ:DMAC) Frequently Asked Questions

How has DiaMedica Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

DiaMedica Therapeutics' stock was trading at $4.00 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, DMAC stock has decreased by 29.8% and is now trading at $2.81. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of DiaMedica Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DiaMedica Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for DiaMedica Therapeutics.

When is DiaMedica Therapeutics' next earnings date?

DiaMedica Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 11th 2020. View our earnings forecast for DiaMedica Therapeutics.

How were DiaMedica Therapeutics' earnings last quarter?

DiaMedica Therapeutics Inc (NASDAQ:DMAC) posted its quarterly earnings results on Monday, March, 23rd. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.04. View DiaMedica Therapeutics' earnings history.

What price target have analysts set for DMAC?

2 analysts have issued 12-month price targets for DiaMedica Therapeutics' shares. Their forecasts range from $8.00 to $11.00. On average, they anticipate DiaMedica Therapeutics' stock price to reach $9.50 in the next year. This suggests a possible upside of 238.1% from the stock's current price. View analysts' price targets for DiaMedica Therapeutics.

Has DiaMedica Therapeutics been receiving favorable news coverage?

News stories about DMAC stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. DiaMedica Therapeutics earned a news impact score of -3.8 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutDiaMedica Therapeutics.

Are investors shorting DiaMedica Therapeutics?

DiaMedica Therapeutics saw a decline in short interest in March. As of March 13th, there was short interest totaling 3,700 shares, a decline of 30.2% from the February 27th total of 5,300 shares. Based on an average trading volume of 40,900 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the shares of the stock are short sold. View DiaMedica Therapeutics' Current Options Chain.

Who are some of DiaMedica Therapeutics' key competitors?

What other stocks do shareholders of DiaMedica Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DiaMedica Therapeutics investors own include Inovio Pharmaceuticals (INO), vTv Therapeutics (VTVT), Agile Therapeutics (AGRX), Amarin (AMRN), Co-Diagnostics (CODX), Crispr Therapeutics (CRSP), Oncolytics Biotech (ONCY), Seelos Therapeutics (SEEL), VBI Vaccines (VBIV) and Vaxart (VXRT).

Who are DiaMedica Therapeutics' key executives?

DiaMedica Therapeutics' management team includes the following people:
  • Mr. Rick Pauls M.B.A., MBA, Pres, CEO & Director (Age 48)
  • Mr. Scott B. Kellen C.A., CFO & Company Sec. (Age 54)
  • Dr. Todd A. Verdoorn, Chief Scientific Officer (Age 57)
  • Mr. Edward B. Rady, Chief Commercial Advisor (Age 70)
  • Dr. Dennis D. Kim M.D., MBA, Consulting Chief Medical Officer (Age 49)

When did DiaMedica Therapeutics IPO?

(DMAC) raised $18 million in an initial public offering on Friday, December 7th 2018. The company issued 4,000,000 shares at a price of $4.00-$5.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO.

What is DiaMedica Therapeutics' stock symbol?

DiaMedica Therapeutics trades on the NASDAQ under the ticker symbol "DMAC."

Who are DiaMedica Therapeutics' major shareholders?

DiaMedica Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (0.15%) and Blair William & Co. IL (0.08%). Company insiders that own DiaMedica Therapeutics stock include Dietrich John Pauls, Harry W Alcorn Jr, Randall Michael Giuffre, Richard D Pilnik and Scott Kellen. View institutional ownership trends for DiaMedica Therapeutics.

Which institutional investors are buying DiaMedica Therapeutics stock?

DMAC stock was acquired by a variety of institutional investors in the last quarter, including Blair William & Co. IL, and Geode Capital Management LLC. Company insiders that have bought DiaMedica Therapeutics stock in the last two years include Dietrich John Pauls, Harry W Alcorn Jr, Randall Michael Giuffre, Richard D Pilnik, and Scott Kellen. View insider buying and selling activity for DiaMedica Therapeutics.

How do I buy shares of DiaMedica Therapeutics?

Shares of DMAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is DiaMedica Therapeutics' stock price today?

One share of DMAC stock can currently be purchased for approximately $2.81.

How big of a company is DiaMedica Therapeutics?

DiaMedica Therapeutics has a market capitalization of $33.61 million and generates $500,000.00 in revenue each year. The company earns $-5,730,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. DiaMedica Therapeutics employs 9 workers across the globe. View additional information about DiaMedica Therapeutics.

What is DiaMedica Therapeutics' official website?

The official website for DiaMedica Therapeutics is http://www.diamedica.com/.

How can I contact DiaMedica Therapeutics?

DiaMedica Therapeutics' mailing address is 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447. The company can be reached via phone at 763-312-6755 or via email at [email protected]


MarketBeat Community Rating for DiaMedica Therapeutics (NASDAQ DMAC)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  64 (Vote Outperform)
Underperform Votes:  87 (Vote Underperform)
Total Votes:  151
MarketBeat's community ratings are surveys of what our community members think about DiaMedica Therapeutics and other stocks. Vote "Outperform" if you believe DMAC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DMAC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Featured Article: Roth IRA

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel